Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus S-1 in advanced esophageal squamous cell carcinoma
NCT05636150Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05636150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636150.